NURS 6531 Final Exam Prep Document | 2026/2027 Edition |
250 Verified Questions
NURS 6531 Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers for the
NURS 6531 Final Exam at Walden University. Each question is accompanied by a detailed rationale
explaining the correct answer and distractor analysis. The content reflects the most current
evidence-based practice guidelines and is designed to help students achieve a high score. Ideal for
last-minute review or systematic study, this resource ensures thorough coverage of key advanced
nursing concepts.
Key Features:
Advanced Health Assessment and Differential Diagnosis
Pharmacology and Therapeutic Management
Chronic Disease Management and Prevention
Acute Care and Emergency Interventions
Ethical and Legal Considerations in Advanced Practice
Evidence-Based Practice and Research Integration
Updates for 2026:
- Updated to reflect 2026-2027 Walden University curriculum changes
- Incorporated latest clinical practice guidelines from leading health organizations
- Added new questions on telehealth and remote patient monitoring
- Revised rationales to include current pharmacological recommendations
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This exam preparation document for NURS 6531 at Walden University comprises 250 verified questions and
answers, each with detailed rationales. The content is meticulously aligned with the latest advanced nursing
practice standards and the 2026-2027 academic curriculum. It covers essential topics including advanced health
assessment, pharmacotherapeutics, chronic disease management, acute care, and ethical decision-making. The
rationales not only justify the correct answer but also explain why each distractor is incorrect, promoting deep
understanding. This resource is designed to facilitate efficient study and boost exam performance, with an
emphasis on clinical reasoning and evidence-based practice. Updated to reflect recent guidelines and emerging
trends in healthcare, it serves as a comprehensive tool for final exam preparation. The document is structured to
support both systematic review and targeted practice, ensuring students are well-prepared for the rigors of the
NURS 6531 final exam.
Keywords:
NURS 6531, Walden University, Final Exam, Advanced Practice Nursing, Verified Questions, Rationales, Exam
Prep, 2026-2027
Answer Format:
Each question is presented with four answer options, one of which is correct. The correct answer is clearly
indicated, followed by a detailed rationale that explains the underlying clinical reasoning. Additionally, each
distractor is analyzed to clarify why it is not the best choice, reinforcing key concepts and preventing common
errors.
Compliance Checklist:
Page 1
, All questions verified against current Walden University NURS 6531 curriculum
Rationales align with evidence-based practice guidelines as of 2026
Distractor explanations address common student misconceptions
Content covers all major exam topics with appropriate weighting
Answers graded A+ standard for accuracy and completeness
Updated to reflect latest pharmacological and therapeutic recommendations
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Health Assessment & 1-50 Comprehensive history taking, physical 20%
Differential Diagnosis examination techniques, diagnostic
reasoning, differential diagnosis
formulation, screening tools
Pharmacology & Therapeutic 51-100 Pharmacokinetics, pharmacodynamics, drug 20%
Management interactions, prescribing for chronic
conditions, adverse effects monitoring,
patient education
Chronic Disease Management 101-150 Diabetes, hypertension, heart failure, COPD, 20%
asthma, chronic kidney disease,
evidence-based treatment protocols, lifestyle
modifications
Acute Care & Emergency 151-200 Sepsis, acute coronary syndrome, stroke, 20%
Interventions respiratory distress, trauma assessment,
emergency pharmacology, rapid response
protocols
Ethical, Legal & Professional 201-225 Informed consent, confidentiality, advance 10%
Issues directives, scope of practice, malpractice
prevention, cultural competence,
interprofessional collaboration
Evidence-Based Practice & 226-250 Critical appraisal of literature, applying 10%
Research research to practice, quality improvement,
outcome measurement, clinical practice
guidelines
Page 2
,Q1. A 45-year-old patient with a history of hypertension and type 2 diabetes presents with a blood pressure
of 148/92 mm Hg on two separate occasions. Current medications are lisinopril 10 mg daily and metformin
1000 mg twice daily. Laboratory results show serum creatinine 1.2 mg/dL, potassium 4.8 mEq/L, and eGFR
55 mL/min/1.73 m². Which antihypertensive agent should be added next to optimize renal outcomes?
A. Amlodipine 5 mg daily
B. Hydrochlorothiazide 25 mg daily
C. Spironolactone 25 mg daily
D. Atenolol 50 mg daily
Correct Answer: A. Amlodipine 5 mg daily
Rationale: In patients with diabetes and chronic kidney disease (eGFR <60), the addition of a calcium channel
blocker (amlodipine) is recommended after maximizing ACE inhibitor/ARB therapy, as it does not worsen renal
function or hyperkalemia. Hydrochlorothiazide loses efficacy at eGFR <30 and may worsen glycemic control.
Spironolactone increases hyperkalemia risk, especially with ACE inhibitor and reduced eGFR. Beta-blockers
(atenolol) are not first-line for uncomplicated hypertension without compelling indications.
Why Wrong:
B - Thiazide diuretics are less effective when eGFR is below 30-45 mL/min and may worsen glycemic control
in diabetes.
C - Spironolactone combined with an ACE inhibitor and reduced eGFR significantly increases the risk of
life-threatening hyperkalemia.
D - Beta-blockers are not recommended as first-line add-on therapy for hypertension without concurrent
coronary artery disease or heart failure.
Reference: Whelton, P.K., et al. (2018). 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and
Management of High Blood Pressure in Adults. J Am Coll Cardiol, 71(19), e127-e248.
Q2. A 30-year-old presents with acute onset of severe right lower quadrant abdominal pain, nausea, and
low-grade fever. On examination, there is rebound tenderness at McBurney's point. White blood cell count is
15,000/µL with left shift. Which of the following is the most appropriate next step in management?
A. Obtain a CT scan of the abdomen with intravenous contrast
B. Obtain a right lower quadrant ultrasound
C. Administer broad-spectrum antibiotics and schedule for appendectomy
D. Perform a diagnostic laparoscopy
Correct Answer: A. Obtain a CT scan of the abdomen with intravenous contrast
Rationale: In non-pregnant adults with suspected acute appendicitis, CT abdomen/pelvis with IV contrast is the
imaging modality of choice due to its high sensitivity and specificity (>95%). Ultrasound is preferred in children
and pregnant women to avoid radiation. While prompt surgical consultation is warranted, definitive imaging is
typically obtained first unless the diagnosis is clinically certain. Diagnostic laparoscopy is reserved for equivocal
cases after imaging.
Why Wrong:
B - Ultrasound is less sensitive in adults and may be limited by bowel gas, making CT the preferred initial
imaging in this population.
C - Administering antibiotics and proceeding directly to surgery without imaging is not standard unless the
diagnosis is unequivocal and imaging would delay care.
D - Diagnostic laparoscopy is invasive and reserved for cases where imaging is inconclusive; it is not the first
step.
Reference: Di Saverio, S., et al. (2020). Diagnosis and treatment of acute appendicitis: 2020 update of the WSES
guidelines. World J Emerg Surg, 15(1), 27.
Page 3
, Q3. Which of the following best describes the mechanism of action of semaglutide in the management of type
2 diabetes?
A. Increases insulin secretion by binding to sulfonylurea receptors on pancreatic beta cells
B. Delays gastric emptying and promotes satiety by activating GLP-1 receptors
C. Inhibits sodium-glucose cotransporter-2 in the proximal renal tubule
D. Decreases hepatic glucose production by activating AMP-kinase in the liver
Correct Answer: B. Delays gastric emptying and promotes satiety by activating GLP-1 receptors
Rationale: Semaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses
glucagon release, slows gastric emptying, and increases satiety, leading to improved glycemic control and weight
loss. Option A describes sulfonylureas; option C describes SGLT2 inhibitors; option D describes metformin.
Why Wrong:
A - Sulfonylureas bind to SUR1 receptors on beta cells to stimulate insulin release, not GLP-1 agonists.
C - SGLT2 inhibitors block glucose reabsorption in the kidney, not GLP-1 receptor activation.
D - Metformin activates AMPK in the liver to reduce gluconeogenesis, not GLP-1 agonists.
Reference: American Diabetes Association. (2023). Pharmacologic Approaches to Glycemic Treatment: Standards
of Care in Diabetes-2023. Diabetes Care, 46(Suppl 1), S140-S157.
Q4. A 55-year-old postmenopausal woman with no prior cancer screening presents for a routine examination.
She has a family history of breast cancer in her mother diagnosed at age 60. The patient is asymptomatic.
Which of the following screening recommendations is most appropriate?
A. Begin annual mammography at age 50
B. Begin biennial mammography at age 50
C. Begin annual mammography at age 40
D. Begin annual mammography and breast MRI at age 40
Correct Answer: C. Begin annual mammography at age 40
Rationale: The USPSTF recommends that women with a first-degree relative with breast cancer (especially if
diagnosed before age 65) begin screening mammography at age 40, and annually thereafter. Average-risk women
may begin at age 50 with biennial screening. Breast MRI is reserved for high-risk women (e.g., BRCA mutation
carriers, lifetime risk >20%), which does not apply here based on the family history given.
Why Wrong:
A - Starting at age 50 is appropriate for average-risk women, but this patient has a first-degree relative with
breast cancer, warranting earlier screening.
B - Biennial screening is for average-risk women starting at age 50; this patient requires annual screening
starting at 40.
D - Breast MRI is not indicated for this level of risk; it is reserved for women with a lifetime risk of 20% or
more or known genetic mutations.
Reference: U.S. Preventive Services Task Force. (2024). Breast Cancer: Screening. Final Recommendation
Statement.
Page 4
250 Verified Questions
NURS 6531 Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED A+.
100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers for the
NURS 6531 Final Exam at Walden University. Each question is accompanied by a detailed rationale
explaining the correct answer and distractor analysis. The content reflects the most current
evidence-based practice guidelines and is designed to help students achieve a high score. Ideal for
last-minute review or systematic study, this resource ensures thorough coverage of key advanced
nursing concepts.
Key Features:
Advanced Health Assessment and Differential Diagnosis
Pharmacology and Therapeutic Management
Chronic Disease Management and Prevention
Acute Care and Emergency Interventions
Ethical and Legal Considerations in Advanced Practice
Evidence-Based Practice and Research Integration
Updates for 2026:
- Updated to reflect 2026-2027 Walden University curriculum changes
- Incorporated latest clinical practice guidelines from leading health organizations
- Added new questions on telehealth and remote patient monitoring
- Revised rationales to include current pharmacological recommendations
- Enhanced distractor explanations to clarify common misconceptions
Abstract:
This exam preparation document for NURS 6531 at Walden University comprises 250 verified questions and
answers, each with detailed rationales. The content is meticulously aligned with the latest advanced nursing
practice standards and the 2026-2027 academic curriculum. It covers essential topics including advanced health
assessment, pharmacotherapeutics, chronic disease management, acute care, and ethical decision-making. The
rationales not only justify the correct answer but also explain why each distractor is incorrect, promoting deep
understanding. This resource is designed to facilitate efficient study and boost exam performance, with an
emphasis on clinical reasoning and evidence-based practice. Updated to reflect recent guidelines and emerging
trends in healthcare, it serves as a comprehensive tool for final exam preparation. The document is structured to
support both systematic review and targeted practice, ensuring students are well-prepared for the rigors of the
NURS 6531 final exam.
Keywords:
NURS 6531, Walden University, Final Exam, Advanced Practice Nursing, Verified Questions, Rationales, Exam
Prep, 2026-2027
Answer Format:
Each question is presented with four answer options, one of which is correct. The correct answer is clearly
indicated, followed by a detailed rationale that explains the underlying clinical reasoning. Additionally, each
distractor is analyzed to clarify why it is not the best choice, reinforcing key concepts and preventing common
errors.
Compliance Checklist:
Page 1
, All questions verified against current Walden University NURS 6531 curriculum
Rationales align with evidence-based practice guidelines as of 2026
Distractor explanations address common student misconceptions
Content covers all major exam topics with appropriate weighting
Answers graded A+ standard for accuracy and completeness
Updated to reflect latest pharmacological and therapeutic recommendations
Content Area Overview:
Content Area Questions Key Topics Weight
Advanced Health Assessment & 1-50 Comprehensive history taking, physical 20%
Differential Diagnosis examination techniques, diagnostic
reasoning, differential diagnosis
formulation, screening tools
Pharmacology & Therapeutic 51-100 Pharmacokinetics, pharmacodynamics, drug 20%
Management interactions, prescribing for chronic
conditions, adverse effects monitoring,
patient education
Chronic Disease Management 101-150 Diabetes, hypertension, heart failure, COPD, 20%
asthma, chronic kidney disease,
evidence-based treatment protocols, lifestyle
modifications
Acute Care & Emergency 151-200 Sepsis, acute coronary syndrome, stroke, 20%
Interventions respiratory distress, trauma assessment,
emergency pharmacology, rapid response
protocols
Ethical, Legal & Professional 201-225 Informed consent, confidentiality, advance 10%
Issues directives, scope of practice, malpractice
prevention, cultural competence,
interprofessional collaboration
Evidence-Based Practice & 226-250 Critical appraisal of literature, applying 10%
Research research to practice, quality improvement,
outcome measurement, clinical practice
guidelines
Page 2
,Q1. A 45-year-old patient with a history of hypertension and type 2 diabetes presents with a blood pressure
of 148/92 mm Hg on two separate occasions. Current medications are lisinopril 10 mg daily and metformin
1000 mg twice daily. Laboratory results show serum creatinine 1.2 mg/dL, potassium 4.8 mEq/L, and eGFR
55 mL/min/1.73 m². Which antihypertensive agent should be added next to optimize renal outcomes?
A. Amlodipine 5 mg daily
B. Hydrochlorothiazide 25 mg daily
C. Spironolactone 25 mg daily
D. Atenolol 50 mg daily
Correct Answer: A. Amlodipine 5 mg daily
Rationale: In patients with diabetes and chronic kidney disease (eGFR <60), the addition of a calcium channel
blocker (amlodipine) is recommended after maximizing ACE inhibitor/ARB therapy, as it does not worsen renal
function or hyperkalemia. Hydrochlorothiazide loses efficacy at eGFR <30 and may worsen glycemic control.
Spironolactone increases hyperkalemia risk, especially with ACE inhibitor and reduced eGFR. Beta-blockers
(atenolol) are not first-line for uncomplicated hypertension without compelling indications.
Why Wrong:
B - Thiazide diuretics are less effective when eGFR is below 30-45 mL/min and may worsen glycemic control
in diabetes.
C - Spironolactone combined with an ACE inhibitor and reduced eGFR significantly increases the risk of
life-threatening hyperkalemia.
D - Beta-blockers are not recommended as first-line add-on therapy for hypertension without concurrent
coronary artery disease or heart failure.
Reference: Whelton, P.K., et al. (2018). 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and
Management of High Blood Pressure in Adults. J Am Coll Cardiol, 71(19), e127-e248.
Q2. A 30-year-old presents with acute onset of severe right lower quadrant abdominal pain, nausea, and
low-grade fever. On examination, there is rebound tenderness at McBurney's point. White blood cell count is
15,000/µL with left shift. Which of the following is the most appropriate next step in management?
A. Obtain a CT scan of the abdomen with intravenous contrast
B. Obtain a right lower quadrant ultrasound
C. Administer broad-spectrum antibiotics and schedule for appendectomy
D. Perform a diagnostic laparoscopy
Correct Answer: A. Obtain a CT scan of the abdomen with intravenous contrast
Rationale: In non-pregnant adults with suspected acute appendicitis, CT abdomen/pelvis with IV contrast is the
imaging modality of choice due to its high sensitivity and specificity (>95%). Ultrasound is preferred in children
and pregnant women to avoid radiation. While prompt surgical consultation is warranted, definitive imaging is
typically obtained first unless the diagnosis is clinically certain. Diagnostic laparoscopy is reserved for equivocal
cases after imaging.
Why Wrong:
B - Ultrasound is less sensitive in adults and may be limited by bowel gas, making CT the preferred initial
imaging in this population.
C - Administering antibiotics and proceeding directly to surgery without imaging is not standard unless the
diagnosis is unequivocal and imaging would delay care.
D - Diagnostic laparoscopy is invasive and reserved for cases where imaging is inconclusive; it is not the first
step.
Reference: Di Saverio, S., et al. (2020). Diagnosis and treatment of acute appendicitis: 2020 update of the WSES
guidelines. World J Emerg Surg, 15(1), 27.
Page 3
, Q3. Which of the following best describes the mechanism of action of semaglutide in the management of type
2 diabetes?
A. Increases insulin secretion by binding to sulfonylurea receptors on pancreatic beta cells
B. Delays gastric emptying and promotes satiety by activating GLP-1 receptors
C. Inhibits sodium-glucose cotransporter-2 in the proximal renal tubule
D. Decreases hepatic glucose production by activating AMP-kinase in the liver
Correct Answer: B. Delays gastric emptying and promotes satiety by activating GLP-1 receptors
Rationale: Semaglutide is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses
glucagon release, slows gastric emptying, and increases satiety, leading to improved glycemic control and weight
loss. Option A describes sulfonylureas; option C describes SGLT2 inhibitors; option D describes metformin.
Why Wrong:
A - Sulfonylureas bind to SUR1 receptors on beta cells to stimulate insulin release, not GLP-1 agonists.
C - SGLT2 inhibitors block glucose reabsorption in the kidney, not GLP-1 receptor activation.
D - Metformin activates AMPK in the liver to reduce gluconeogenesis, not GLP-1 agonists.
Reference: American Diabetes Association. (2023). Pharmacologic Approaches to Glycemic Treatment: Standards
of Care in Diabetes-2023. Diabetes Care, 46(Suppl 1), S140-S157.
Q4. A 55-year-old postmenopausal woman with no prior cancer screening presents for a routine examination.
She has a family history of breast cancer in her mother diagnosed at age 60. The patient is asymptomatic.
Which of the following screening recommendations is most appropriate?
A. Begin annual mammography at age 50
B. Begin biennial mammography at age 50
C. Begin annual mammography at age 40
D. Begin annual mammography and breast MRI at age 40
Correct Answer: C. Begin annual mammography at age 40
Rationale: The USPSTF recommends that women with a first-degree relative with breast cancer (especially if
diagnosed before age 65) begin screening mammography at age 40, and annually thereafter. Average-risk women
may begin at age 50 with biennial screening. Breast MRI is reserved for high-risk women (e.g., BRCA mutation
carriers, lifetime risk >20%), which does not apply here based on the family history given.
Why Wrong:
A - Starting at age 50 is appropriate for average-risk women, but this patient has a first-degree relative with
breast cancer, warranting earlier screening.
B - Biennial screening is for average-risk women starting at age 50; this patient requires annual screening
starting at 40.
D - Breast MRI is not indicated for this level of risk; it is reserved for women with a lifetime risk of 20% or
more or known genetic mutations.
Reference: U.S. Preventive Services Task Force. (2024). Breast Cancer: Screening. Final Recommendation
Statement.
Page 4
